Kidney failure after living kidney donation in Australia: A national registry linkage study 2004-2023
Authors
Affiliations
Abstract
Background: Living kidney donation is a core part of transplantation and is associated with better graft and patient survival than deceased donor transplantation. Living donors deserve contemporary and locally relevant estimates of long-term kidney failure risk to support informed decision-making. While US cohort studies suggest living donors have a higher relative risk of kidney failure than healthy nondonors, the absolute risk remains low. In Australia, where health systems, demographics and donation practices differ, national estimates of post-donation kidney failure treated with kidney replacement therapy (KRT) are lacking. We linked records from the Australia and New Zealand Living Kidney Donor Registry (ANZLKD) and the Australia and New Zealand Dialysis and Transplant Registry (ANZDATA) to estimate the incidence and absolute risk of kidney failure treated with KRT after living kidney donation.
Methods: We conducted a population-based cohort study of Australian living kidney donors donating between 2004 (establishment of ANZLKD) and 2023. Donor data were collected in ANZLKD and record linkage with ANZDATA was used to ascertain KRT initiation. Follow-up commenced at donation and ended at the earliest of KRT initiation (dialysis or pre-emptive transplantation), death, or 31 December 2023. Incidence rates were calculated per 10,000 person-years with Poisson 95% confidence intervals (CI). Absolute risk at 10 and 15 years was estimated using Kaplan-Meier (censoring deaths) and competing-risk methods (death as a competing event).
Results: The cohort included 5,037 donors, contributing 51,869 person-years of follow-up (median 10.47 (IQR, 5.61-15.15) years). Median age at donation was 51 years (IQR, 43-59) and 57.3% of donors were women. Median serum creatinine at donation was 71 μmol/L (IQR, 63-82) and median measured glomerular filtration rate was 106 mL/min/1.73 m² (IQR, 93-121).
Three donors commenced KRT during follow-up at a median of 13.27 years (IQR, 11.02-15.31) after donation. The incidence rate of KRT was 0.58 per 10,000 person-years (95%CI, 0.12-1.69). The death-censored Kaplan-Meier estimate of cumulative incidence was 0% at 10 years and 0.10% at 15 years (95%CI, 0.02%-0.39%), equivalent to 10 per 10,000 donors (95%CI, 2-39). In competing-risk analyses treating death as a competing event, the cumulative incidence of KRT 9.5 per 10,000 at 15 years (95%CI, 2.0-33.7).The primary cause of kidney failure was renal cell carcinoma and hypertensive nephropathy.
Conclusions: Using national linkage of ANZLKD and ANZDATA, we provide the first Australian estimates of kidney failure treated with KRT after living kidney donation. KRT after donation was very rare: no observed events within 10 years and an approximately 10-per-10,000 risk by 15 years. Although limited by the small number of outcomes and absence of a non-donor comparator, these data provide contemporary, locally relevant absolute risk estimates to support counselling and consent.